Supriya Lifescience: Business Overview & Financial Analysis
Supriya Lifescience is a generic pharmaceutical manufacturing enterprise headquartered in Mumbai, Maharashtra. Promoted by Dr. Satish Waman Wagh, the enterprise develops, manufactures, and exports Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and specialized intermediates. Operating advanced manufacturing facilities in Lote Parshuram and Ambernath, Maharashtra, the company delivers healthcare solutions across 120+ countries, maintaining a primary therapeutic focus across antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics.
Business Overview & Product Portfolio of Supriya Lifescience (FY2026)
Supriya Lifescience operates an integrated active pharmaceutical ingredient manufacturing business model serving regulated and semi-regulated global markets.
- Active Pharmaceutical Ingredients (API) Portfolio Scale – 40+ commercial APIs
- Core Therapeutic Focus Areas – Antihistamine, Anaesthetic, Anti-Asthmatic, Vitamin, and Anti-Allergic
- Export Market Revenue Contribution – 81.0% of Total Revenue
- Domestic Indian Market Share – 19.0% of Total Revenue
- Flagship API Product Suite – Chlorpheniramine Maleate, Ketamine Hydrochloride, Cetirizine DiHCl, and Salbutamol Sulphate
Export shipments account for over four-fifths of total turnover, establishing a diversified global distribution network. Dominant market positions in core molecules like Chlorpheniramine Maleate and Ketamine Hydrochloride anchor baseline revenues.
Geographic Revenue Breakdown of Supriya Lifescience (Q1 FY2027)
Supriya Lifescience exports active ingredients across major regulated pharmaceutical markets in Europe, Asia, and the Americas.
- Asia Region Revenue Share – 39.0% of Total Revenue (vs 32.0% in Q1 FY2026)
- Europe Region Revenue Share – 35.0% of Total Revenue (vs 41.0% in Q1 FY2026)
- Latin America (LATAM) Share – 20.0% of Total Revenue (vs 17.0% in Q1 FY2026)
- North America Region Share – 3.0% of Total Revenue
- Rest of the World (ROW) Share – 3.0% of Total Revenue
- Global Export Footprint Scale – Active dispatches across 120+ countries
Expanding presence across Asian and Latin American markets drove quarterly sales volume growth. Sustaining strong customer relationships in European markets provides high gross realisations.
Therapeutic Segment Breakdown of Supriya Lifescience (Q1 FY2027)
The company categorises its API turnover across distinct therapeutic applications based on global healthcare demand.
- Anaesthetics Segment Revenue Share – 48.0% of Total Revenue
- Vitamins Segment Revenue Share – 17.0% of Total Revenue
- Anti-Asthmatic Segment Revenue Share – 9.0% of Total Revenue
- Anti-Histamine Segment Revenue Share – 9.0% of Total Revenue
- Anti-Allergic Segment Revenue Share – 4.0% of Total Revenue
- Analgesics Segment Revenue Share – 3.0% of Total Revenue
Anaesthetic APIs represent nearly half of quarterly turnover, serving as the largest single product vertical. Scaling vitamin and anti-asthmatic shipments provides multi-category revenue growth.
Manufacturing Facilities & Capacity Scale of Supriya Lifescience (FY2026)
Supriya Lifescience manages automated synthesis complexes equipped with multi-purpose reaction blocks and analytical testing laboratories.
- Total API Reactor Capacity Base – 1,020+ Kilolitres (KL) across two sites
- Main Manufacturing Hub Location – Lote Parshuram (Maharashtra) with 932 KL reactor capacity
- Secondary Facility Location – Ambernath (Maharashtra) CDSCO GMP-certified site
- Regulatory Approvals Held – USFDA, EDQM, EUGMP, Health Canada, and NMPA China
- Module E Production Block Expansion – +55% capacity addition (from 597 KL to 932 KL)
Operating 1,020+ KL of reactor capacity across Lote Parshuram and Ambernath enables large-scale API synthesis. Stringent regulatory certifications from USFDA and EDQM support product access into key export destinations.
Latest Quarterly Financial Performance of Supriya Lifescience (Q1 FY2027)
Supriya Lifescience recorded top-line revenue expansion during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 189.75 crore (+30.8% YoY vs Rs 145.07 crore in Q1 FY2026)
- Consolidated Total Income – Rs 192.40 crore (+32.6% YoY vs Rs 145.07 crore)
- Consolidated Operating EBITDA – Rs 47.46 crore (-8.2% YoY vs Rs 51.70 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 25.00% (vs 35.60% in Q1 FY2026)
- Profit Before Tax (PBT) – Rs 40.79 crore (-14.0% YoY vs Rs 47.41 crore in Q1 FY2026)
- Consolidated Net Profit After Tax (PAT) – Rs 24.04 crore (-30.9% YoY vs Rs 34.79 crore in Q1 FY2026)
- Consolidated Net PAT Margin – 12.70% (vs 24.00% in Q1 FY2026)
- Diluted Earnings Per Share (EPS) – Rs 2.99 per share
First-quarter revenue expanded 30.8% year-on-year to Rs 189.75 crore, supported by volume off-take in Asia and Latin America. Consolidated Net Profit After Tax reached Rs 24.04 crore, as temporary product mix shifts compressed operating margins.
Balance Sheet Structure & Financial Health of Supriya Lifescience (Q1 FY2027)
Supriya Lifescience maintains a capital structure supported by equity retention, liquid cash reserves, and disciplined working capital.
- Financial Debt Status – Zero Net Debt / Net Cash Surplus
- Total Shareholder Equity Net Worth Base – ~Rs 850.00 crore
- Working Capital Management – Efficient raw material sourcing and trade receivable collection
- Credit Rating Profile – High investment-grade rating profile
Operating a net debt-free financial structure provides full operational flexibility to execute capital outlays. Strong shareholder equity backing ensures long-term balance sheet stability.
Capex Outlay & Business Expansion Pipeline of Supriya Lifescience (FY2027–FY2028)
The enterprise executes capital allocation plans to scale commercial production, expand CDMO partnerships, and upgrade R&D infrastructure.
- Ambernath Facility Commercial Ramp-Up – Scaling new API and intermediate production blocks
- R&D Center Integration – Advanced analytical and process research labs at Lote Parshuram
- CDMO Business Expansion Target – Scaling custom synthesis projects with global pharmaceutical partners
- Target Revenue Growth Guidance – 20.0%+ annual top-line revenue CAGR target
- Funding Method – 100% funded through internal cash accruals and IPO proceeds
Commercializing the Ambernath site expands manufacturing capacity for new generic launches. Scaling CDMO partnerships leverages in-house chemistry capabilities to build multi-year contractual cash flows.
Strategic Outlook & Management Commentary of Supriya Lifescience (Q1 FY2027 Concall)
Management guidance outlines strategic growth priorities centered on top-line revenue acceleration, margin recovery, and CDMO scaling.
- Management targets maintaining a 20.0%+ annual top-line revenue growth trajectory throughout FY2027.
- Consolidated operating EBITDA margins are projected to recover toward the 28.0%–30.0% corridor as therapeutic mix normalises.
- Regional diversification into Asian and Latin American markets will drive sales volume growth across core molecules.
- Production ramp-up at the CDSCO-approved Ambernath facility will add high-value API capacity.
- Custom Development and Manufacturing Organisation (CDMO) partnerships are being expanded with global innovators.
- Capital allocation strategy will prioritize self-funded capacity additions while maintaining a zero net debt balance sheet.
Management anticipates strong global demand for active ingredients, supporting full-year turnover growth. Operational focus centers on commercializing Ambernath production blocks, optimizing process chemistry, and restoring operating EBITDA margins.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Supriya Lifescience Q1 FY2027 Unaudited Financial Disclosures & Press Notes (August 13, 2026)
- Supriya Lifescience Q1 FY2027 Earnings Conference Call Transcript & Investor Summary (August 14, 2026)
- Supriya Lifescience Corporate Presentation & Regulatory Stock Exchange Outcomes
- BSE Limited & National Stock Exchange of India (NSE) Filings for Supriya Lifescience
- Ticker Finology Supriya Lifescience Page
Disclaimer
The information presented above on Supriya Lifescience has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Supriya Lifescience page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.